Anzeige
Mehr »
Dienstag, 14.07.2026 - Börsentäglich über 12.000 News
Time to Buy! Diese drei Kräfte treiben die Tiefsee-Exploration massiv an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JD8X | ISIN: US92243A2006 | Ticker-Symbol: NB11
Stuttgart
30.03.26 | 15:20
0,600 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VAXART INC Chart 1 Jahr
5-Tage-Chart
VAXART INC 5-Tage-Chart

Aktuelle News zur VAXART Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.07.Vaxart, Inc. - 8-K, Current Report3
06.07.Vaxart reports safety data from oral COVID vaccine trial4
06.07.Vaxart, Inc.: Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine88No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart...
► Artikel lesen
01.07.Vaxart legt Stimmrechtsstreit bei und erweitert Aufsichtsrat3
VAXART Aktie jetzt für 0€ handeln
01.07.Vaxart, Inc.: Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements123Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN...
► Artikel lesen
26.06.Vaxart, Inc. - 8-K, Current Report3
26.06.Vaxart, Inc.: Vaxart Publishes Presentation Urging Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY4
25.06.Vaxart, Inc.: Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial1
16.06.Vaxart, Inc.: Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting313Urges Stockholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif....
► Artikel lesen
09.06.Vaxart, Inc.: Vaxart to Participate in BTIG Infectious Disease Day 20262
08.06.Vaxart, Inc.: Vaxart Urges Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY2
01.06.Vaxart, Inc.: Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders271Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing...
► Artikel lesen
19.05.Vaxart, Inc. - 8-K, Current Report1
19.05.Vaxart faces proxy contest ahead of July annual meeting2
19.05.Vaxart, Inc.: Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders289Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders...
► Artikel lesen
09.05.Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release7
08.05.Vaxart mit gemischten Q1-Zahlen: Gewinn übertrifft Prognose, doch Umsatzenttäuschung belastet Aktie9
08.05.Vaxart, Inc. - S-1, General form for registration of securities1
07.05.Vaxart GAAP EPS of $0.02 in-line, revenue of $39.2M misses by $26.3M4
07.05.Vaxart, Inc. - 10-Q, Quarterly Report-
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1